CEPHEUS and PERSEUS Trials: Daratumumab Plus Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

home / between-the-lines / cepheus-and-perseus-trials-daratumumab-plus-bortezomib-lenalidomide-and-dexamethasone-for-newly

Panelists discuss how CD38 antibody–based four-drug regimens are transforming frontline multiple myeloma treatment by improving efficacy, deepening and sustaining MRD responses, and expanding use across patient populations through individualized dosing—establishing a new standard of care while paving the way for integration of novel immunotherapies and potential shifts in transplant strategy.